Since the activity of AMPK is reduced in obesity and NAFLD9,14,15, increasing AMPK activity has been suggested as an attractive therapeutic option for treating metabolic disorders, including NAFLD. The gene discussed is PRKAA1; the disease is metabolic dysfunction-associated steatotic liver disease.